Stocks in the Hong Kong market | Zhonghui Biosciences-B(02627.HK) rose more than 3% as the application for the quadrivalent influenza virus subunit vaccine was approved by the National Medical Products Administration.
According to the Choice Financial News APP, SinoMab-B (02627.HK) rose more than 3%, as of the time of publication, it rose 2.71% to HK$50.4, with a turnover of HK$5.0766 million.
Latest
